{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:32:07Z","timestamp":1790652727813,"version":"4.1.0"},"reference-count":111,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Basal cell carcinoma (BCC) is the most common malignant tumor in light\u2010skinned people and amounts to about 75\u00a0% of all cases of skin cancer. Increasing incidence rates have been reported for decades all over the world. The main risk factors include UV radiation, male sex, light skin type, advanced age, long\u2010term immunosuppression, a positive individual or family history, and certain genodermatoses. BCC metastasizes only rarely, and its mortality is low, but it is associated with significant morbidity. Genetic mutations especially in the hedgehog pathway play an important role in BCC pathogenesis. Non\u2010invasive procedures such as optical coherence tomography or confocal laser scan microscopy are increasingly utilized for diagnostics in addition to visual inspection and dermatoscopy, but only in exceptional cases can histological confirmation of the diagnosis be dispensed with. Various clinical and histological subtypes have been defined. Differentiating between BCC with high and low risk of recurrence has a significant influence on the choice of treatment. Most BCC can be treated effectively and safely with standard surgery, or in selected cases with topical treatment. Locally advanced and metastasized BCC must be treated with radiation or systemic therapy. Radiation is also an option for older patients with contraindications for surgery. The hedgehog inhibitors vismodegib and sonidegib are currently approved for systemic therapy of BCC in Europe. Approval for the PD1 inhibitor cemiplimab as second\u2010line therapy is expected in the near future.<\/jats:p>","DOI":"10.1111\/ddg.14580","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T03:49:21Z","timestamp":1626839361000},"page":"1021-1041","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Known and new facts on basal cell carcinoma"],"prefix":"10.1111","volume":"19","author":[{"given":"Magdalena","family":"Seidl\u2010Philipp","sequence":"first","affiliation":[{"name":"University Hospital for Dermatology Venereology and Allergology Medical University Innsbruck Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Frischhut","sequence":"additional","affiliation":[{"name":"University Hospital for Dermatology Venereology and Allergology Medical University Innsbruck Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"H\u00f6llweger","sequence":"additional","affiliation":[{"name":"University Hospital for Dermatology Venereology and Allergology Medical University Innsbruck Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schmuth","sequence":"additional","affiliation":[{"name":"University Hospital for Dermatology Venereology and Allergology Medical University Innsbruck Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Anh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"University Hospital for Dermatology Venereology and Allergology Medical University Innsbruck Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10830.x"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.06.003"},{"issue":"1","key":"e_1_2_9_4_1","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/ddg.13733","article-title":"S2k guidelines for cutaneous basal cell carcinoma \u2013 part 1: epidemiology, genetics and diagnosis","volume":"17","author":"Lang BM","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"e_1_2_9_5_1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/ddg.13755","article-title":"S2k guidelines for cutaneous basal cell carcinoma \u2013 part 2: treatment, prevention and follow\u2010up","volume":"17","author":"Lang BM","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2015.02.006"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncb2031"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra044151"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4725.1999.99047.x"},{"key":"e_1_2_9_10_1","unstructured":"Krebs in Deutschland f\u00fcr 2013\/2014. 11. Ausgabe. Robert Koch\u2010Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg).Berlin 2017"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.02.050"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15321"},{"key":"e_1_2_9_13_1","unstructured":"Krebserkrankungen in \u00d6sterreich. STATISTIK AUSTRIA2018."},{"issue":"8","key":"e_1_2_9_14_1","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/ddg.12690","article-title":"Incidence trends of nonmelanoma skin cancer in Germany from 1998 to 2010","volume":"13","author":"Rudolph C","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_9_15_1","unstructured":"Krebs in Deutschland f\u00fcr 2015\/2016. 12. Ausgabe. Robert Koch\u2010Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg).Berlin 2019"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.1188"},{"key":"e_1_2_9_17_1","first-page":"481e91.86","article-title":"Basal cell carcinoma: what's new under the sun","author":"Dessinioti C","year":"2010","journal-title":"Photochem Photobiol"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.06.020"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0000000000001217"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-021-04818-0"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14153"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.03.010"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.276"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3525"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18112485"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81268-4"},{"key":"e_1_2_9_27_1","unstructured":"OMIM 109400 Available from:https:\/\/www.omim.org\/entry\/109400[Last accessed November 7 2020]."},{"key":"e_1_2_9_28_1","first-page":"26","volume-title":"WHO Classification of Skin tumors","author":"Messina J","year":"2018"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2113"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14458"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2016.0065"},{"key":"e_1_2_9_32_1","unstructured":"National Comprehensive Cancer Center.NCCN clinical practice guidelines in oncology; Basal Cell Skin Cancer (V2.2021). Available from:www.nccn.org. [Last accessed April 10 2021]"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.083"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14657"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.12.038"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.12.026"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14499"},{"key":"e_1_2_9_38_1","first-page":"203","article-title":"Optische Koh\u00e4renztomographie \u2013 Eine Methode zur Diagnostik und Therapiekontrolle bei nicht\u2010melanozyt\u00e4ren Hauttumoren unter photodynamischer Therapie","volume":"04","author":"Ulrich M","year":"2017","journal-title":"Haut"},{"issue":"12","key":"e_1_2_9_39_1","first-page":"CD013189","article-title":"Cochrane Skin Cancer Diagnostic Test Accuracy Group. Optical coherence tomography for diagnosing skin cancer in adults","volume":"12","author":"Ferrante di Ruffano L","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/srt.12407"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16154"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12196"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-015-3632-y"},{"issue":"12","key":"e_1_2_9_44_1","first-page":"CD013191","article-title":"Cochrane Skin Cancer Diagnostic Test Accuracy Group. Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults","volume":"12","author":"Dinnes J","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2016.04.010"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.049"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.012"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.014"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2017.01.185"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.04.007"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17507"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15243"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.10.028"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.2446"},{"key":"e_1_2_9_55_1","first-page":"CD003412","article-title":"Interventions for basal cell carcinoma of the skin","volume":"11","author":"Thomson J","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.140_12665"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.08.018"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjps.2015.03.012"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0b013e3181ea450d"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2019.05.002"},{"issue":"7","key":"e_1_2_9_61_1","article-title":"Mikroskopisch kontrollierte Chirurgie bei malignen Hauttumoren","volume":"104","author":"Breuninger H","year":"2007","journal-title":"Dtsch Arztebl"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12689"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.11.066"},{"key":"e_1_2_9_64_1","unstructured":"Fachinformation Aldara 5 % Cr\u00e8me. Available from:www.ema.europa.eu\/en\/documents\/product\u2010information\/aldara\u2010epar\u2010product\u2010information_de.pdf[Last accessed June 7 2021]."},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.10.019"},{"key":"e_1_2_9_66_1","unstructured":"Fachinformation Efudix. Available from:https:\/\/compendium.ch\/product\/21171\/mpro?idType=monographienumber[Last accessed June 7 2021]."},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.09.033"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.e21626"},{"key":"e_1_2_9_69_1","unstructured":"www.clinicaltrials.gov[Last accessed on February 26 2021]."},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16017"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16838"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.02803.x"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.1.17"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2008.04022.x"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03877.x"},{"issue":"5","key":"e_1_2_9_76_1","first-page":"547","article-title":"Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial","volume":"18","author":"Basset\u2010Seguin N","year":"2008","journal-title":"Eur J Dermatol"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.9.1131"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16441"},{"key":"e_1_2_9_79_1","unstructured":"Fachinformation Ameluz\u2010Gel. Availabele from:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/ameluz\u2010epar\u2010product\u2010information_de.pdf[Last accessed June 7 2021]."},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14004"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00562-8"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000002339"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2020.01.001"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1709119"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0678"},{"key":"e_1_2_9_86_1","unstructured":"https:\/\/www.oncobeta.com\/de\/rhenium\u2010sct\u2010information\u2010de[Last accessed June 7 2021]."},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1793890"},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16230"},{"key":"e_1_2_9_89_1","unstructured":"FDA approves Libtayo\u00ae (Cemiplimab\u2010rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma. Available from:www.globenewswire.com\/fr\/newsrelease\/2021\/02\/09\/2172711\/0\/en\/FDA\u2010approves\u2010Libtayo\u2010Cemiplimab\u2010rwlc\u2010as\u2010first\u2010immunotherapy\u2010indicated\u2010for\u2010patients\u2010with\u2010advanced\u2010basal\u2010cell\u2010carcinoma.html[Last accessed June 7 2021]."},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.12.013"},{"key":"e_1_2_9_91_1","unstructured":"Fachinformation Erivedge. Available from:www.ema.europa.eu\/en\/documents\/product\u2010information\/erivedge\u2010epar\u2010product\u2010information_de.pdf[Last accessed June 7 2021]."},{"key":"e_1_2_9_92_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3286-5"},{"key":"e_1_2_9_93_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.5657"},{"key":"e_1_2_9_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.08.022"},{"key":"e_1_2_9_95_1","unstructured":"Fachinformation Odomzo. Available from:https:\/\/ec.europa.eu\/health\/documents\/community\u2010register\/2015\/20150814132561\/anx_132561_de.pdf[Last accessed June 7 2021]."},{"key":"e_1_2_9_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18552"},{"key":"e_1_2_9_97_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15367"},{"key":"e_1_2_9_98_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0186"},{"key":"e_1_2_9_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.12.006"},{"key":"e_1_2_9_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30072-4"},{"key":"e_1_2_9_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30566-6"},{"key":"e_1_2_9_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.02.027"},{"key":"e_1_2_9_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19501"},{"key":"e_1_2_9_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.11.001"},{"issue":"15","key":"e_1_2_9_105_1","first-page":"9509","article-title":"Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open\u2010label, phase 2 trial (VISMONEO study)","volume":"36","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_9_106_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0386"},{"key":"e_1_2_9_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.077"},{"key":"e_1_2_9_108_1","unstructured":"StratigosA SekulicA PerisKet\u00a0al.Primary Analysis of Phase 2 Results for Cemiplimab in Patients (pts) with Locally Advanced Basal Cell Carcinoma (laBCC) who Progress on or are Intolerant to Hedgehog Inhibitors (HHIs). Available fromhttps:\/\/jofskin.org\/index.php\/skin\/article\/view\/1156[Last accessed June 7 2021]."},{"key":"e_1_2_9_109_1","unstructured":"FDA approves cemiplimab\u2010rwlc for locally advanced and metastatic basal cell carcinoma. Available from:www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010approves\u2010cemiplimab\u2010rwlc\u2010locally\u2010advanced\u2010and\u2010metastatic\u2010basal\u2010cell\u2010carcinoma[Last accessed June 7 2021]."},{"key":"e_1_2_9_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.08.017"},{"key":"e_1_2_9_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.05.010"},{"key":"e_1_2_9_112_1","unstructured":"S3\u2010Leitlinie Pr\u00e4vention von Hautkrebs Version 2.0 \u2013 M\u00e4rz 2021 AWMF Registernummer: 032\/052OL Available from:https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/032\u2010052OLl_S3_Praevention\u2010Hautkrebs_2021\u201003.pdf[Last accessed June 7 2021]."}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.14580","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ddg.14580","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.14580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T03:46:08Z","timestamp":1699242368000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.14580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":111,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1111\/ddg.14580"],"URL":"https:\/\/doi.org\/10.1111\/ddg.14580","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"2021-05-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}